Sotalol: A beta blocker with unique antiarrhythmic properties

Singh, Bramah N.; Nademanee, Koonlawee

doi:10.1016/0002-8703(87)90316-4

Cited by 81 publications

(18 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Association of Q-T prolongation with bradycardia and hypokalaemia has been clinically associated with arrhythmias, particularly Torsade de Pointes (Bacaner et al, 1986;Singh, 1987;Surawicz, 1987;1989). The importance of K+ channels in maintaining and terminating cardiac action potentials is recognized (Noma, 1987;Cook, 1988).…”

Section: Discussionmentioning

confidence: 99%

Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K⁺ current blocker

Beatch

Abraham

MacLeod

et al. 1991

British J Pharmacology

View full text Add to dashboard Cite

1Rats were used to evaluate the antiarrhythmic properties of tedisamil, a novel agent with the electrophysiological properties of a Class III antiarrhythmic drug. Tedisamil was tested against coronary artery occlusion-induced arrhythmias in conscious animals. 2 The actions of tedisamil on the ECG, as well as responses to electrical stimulation, were compared with those on the configuration of epicardial intracellular action potentials recorded in vivo. 3 Tedisamil (1-4mgkg-1, i.v.) caused bradycardia, elevated blood pressure and dose-dependently reduced ventricular fibrillation (VF) induced by occlusion of the left anterior descending coronary artery. Other ischaemia-associated arrhythmias were not so well suppressed. Antiarrhythmic activity was greatest when the tedisamil-induced bradycardia was prevented by electrically-pacing the left ventricle. 4 Tedisamil dose-dependently lengthened the effective refractory period and prevented electricallyinduced VF. In vivo, i.v.) prolonged the duration of epicardial intracellular action potentials by up to 400%. 5 Results showed that tedisamil possessed antifibrillatory actions in rats that were related to Class III electrophysiological actions as revealed by electrical stimulation and electrophysiological analyses.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K⁺ current blocker

Beatch

Abraham

MacLeod

et al. 1991

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…There were no missing envelopes. With 15 centers participating, 13 may have had one more patient in the sotalol group, which may explain the uneven distribution.…”

Section: Discussionmentioning

confidence: 99%

“…Heart volume measured on the biplane chest x-ray investigation were not to exceed 700 ml/m2 of the body surface area for men or 650 ml/m2 for women. 13 The patients were followed in the outpatient clinic at 1, 3, and 6 months. A 12-lead resting electrocardiogram (ECG) was recorded, and laboratory blood tests were performed.…”

Section: Methodsmentioning

confidence: 99%

“…[8][9][10][11][12] Sotalol is a ,3-blocking drug with class III antiarrhythmic properties. 13 In patients with atrial fibrillation after open heart surgery, sotalol has been shown to be superior to digitalis and disopyramide in converting atrial fibrillation in the early postoperative phase after coronary artery bypass grafting. 14 The present study was undertaken to compare the efficacy and safety of quinidine and sotalol in maintaining sinus rhythm after DC conversion of atrial fibrillation in patients selected on clinical grounds as suitable for this procedure.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

1990

View full text Add to dashboard Cite

This open, parallel-group study compares quinidine and sotalol treatment for maintenance of sinus rhythm after direct current conversion of patients with chronic atrial fibrillation. The patients from 15 centers in Sweden were randomized to sotalol (98 patients) or quinidine (85 patients) after 2 hours of sinus rhythm after direct current conversion. According to primary efficacy assessment, 52% of the patients in the sotalol group and 48% of the patients in the quinidine group remained in sinus rhythm during the following 6-month treatment period (NS). Furthermore, 34% of the patients treated with sotalol and 22% of the patients treated with quinidine relapsed into atrial fibrillation (NS). Heart rate after relapsing into atrial fibrillation was higher in the patients treated with quinidine (109 beats/min) than in the patients treated with sotalol (78 beats/min, p

show abstract

“…Sotalol is a ␤-blocker with class III AA property 21 that is known to increase HRV in patients with organic heart disease. 22 During control conditions, patients treated with either ␤-blockers or dl-sotalol showed similar HRV, but it was more pronounced than that in patients without AA drugs.…”

Section: Patients With Aa Drugsmentioning

confidence: 99%

Heart Rate Dynamics at the Onset of Ventricular Tachyarrhythmias as Retrieved From Implantable Cardioverter-Defibrillators in Patients With Coronary Artery Disease

et al. 2000

View full text Add to dashboard Cite

Background-The recent availability of implantable cardioverter-defibrillators (ICDs) that record 1024 R-R intervals preceding a ventricular tachyarrhythmia (VTA) provides a unique opportunity to analyze heart rate variability (HRV) before the onset of VTA. Methods and Results-Fifty-eight post-myocardial infarction patients with an implanted ICD for recurrent VTA provided 2 sets of 98 heart rate recordings in sinus rhythm: (1) before a VTA and (2) during control conditions. Three subgroups were considered according to the antiarrhythmic (AA) drug regimen. A state of sympathoexcitation was suggested by the significant reduction in HRV before VTA onset compared with control conditions. ␤-Blockers and dl-sotalol enhanced HRV in control recordings; nevertheless, HRV declined before VTA independent of AA drugs. A gradual increase in heart rate and decrease in sinus arrhythmia at VTA onset were specific findings of patients who received dl-sotalol. Conclusions-The peculiar heart rate dynamics observed before VTA onset are suggestive of a state of sympathoexcitation that is independent of AA drugs.

show abstract

Sotalol: A beta blocker with unique antiarrhythmic properties

Cited by 81 publications

References 97 publications

Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K⁺ current blocker

Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K⁺ current blocker

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

Heart Rate Dynamics at the Onset of Ventricular Tachyarrhythmias as Retrieved From Implantable Cardioverter-Defibrillators in Patients With Coronary Artery Disease

Contact Info

Product

Resources

About

Sotalol: A beta blocker with unique antiarrhythmic properties

Cited by 81 publications

References 97 publications

Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K+ current blocker

Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K+ current blocker

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

Heart Rate Dynamics at the Onset of Ventricular Tachyarrhythmias as Retrieved From Implantable Cardioverter-Defibrillators in Patients With Coronary Artery Disease

Contact Info

Product

Resources

About

Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K⁺ current blocker

Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K⁺ current blocker